Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 3/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | GLI1 | P08151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961557 | 1.00 | PTPN1 (0.58) | PTPN1NT5EALBNR1H4GLI1 | |
| SCHEMBL16848397 | 0.92 | PTPN1 (0.57) | PTPN1NT5EGLI1MAPTATM | |
| SCHEMBL960779 | 0.92 | PTPN1 (0.57) | PTPN1NT5EGLI1MAPTATM | |
| SCHEMBL967221 | 0.90 | PTPN1 (0.70) | PTPN1NT5EALBGLI1MAPT | |
| SCHEMBL14767367 | 0.84 | PTPN1 (0.81) | PTPN1NT5EALBNR1H4PRKCD | |
| SCHEMBL29402973 | 0.77 | PTPN1 (0.77) | PTPN1NT5ENR1H4PRKCDCETP | |
| SCHEMBL14156443 | 0.77 | PTPN1 (0.77) | PTPN1NT5ENR1H4PRKCDCETP | |
| SCHEMBL14156476 | 0.77 | PTPN1 (0.77) | PTPN1NT5ENR1H4PRKCDCETP | |
| SCHEMBL13403512 | 0.74 | PTPN1 (0.87) | PTPN1NT5ENR1H4PRKCDEGLN2 | |
| SCHEMBL14163456 | 0.74 | PTPN1 (0.87) | PTPN1NT5ENR1H4PRKCDEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067966-B2 | Lupeol-type triterpene derivatives as antivirals | HETERO RESEARCH FOUNDATION, HETERO DRUGS LTD. (IN) | 2015-06-30 | — | — | US | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | PTPN1 3935/4885NT5E 1020/4885ALB 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.